- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04192695
Esophageal Squamous Cell Cancer Surveillance With Cytosponge
Surveillance and Early Detection of Esophageal Squamous Cell Carcinoma With Minimally-invasive Cytosponge™ Cell Collection Device Coupled With Molecular Biomarkers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jaroslaw Regula, M.D., PhD
- Phone Number: +48 546 23 28
- Email: jaroslaw.regula@coi.pl
Study Contact Backup
- Name: Wladyslaw Januszewicz, M.D.
- Phone Number: +48 546 23 28
- Email: w.januszewicz@gmail.com
Study Locations
-
-
-
Warsaw, Poland, 02-781
- Recruiting
- Medical Centre for Postgraduate Education
-
Contact:
- Jaroslaw Regula, M.D., PhD
- Phone Number: +48 546 23 28
- Email: jaroslaw.regula@coi.pl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients with esophageal squamous cell cancer (ESCC):
- Patients ≥18 years of with adequate performance status for endoscopy
- Newly diagnosed ESCC suitable for endoscopic or oncological treatment (Rth/Chth)
- Patients currently undergoing oncological treatment (Rth/Chth)
- Consent to provide tissue samples for the study
- Dysphagia grade ≤2 (able to swallow mixed foods and tablets)
Patients at high risk for ESCC:
- Patients ≥18 years of age with adequate performance status for endoscopy
- Prior definitive treatment for head and neck cancer (cancer of the oral cavity, hypopharyngeal cancer, laryngeal carcinoma) and at least 12 months post-therapy (both Rth, Chth, and combination treatment)
- Prior definitive endoscopic treatment for early ESCC in the past (at least 6 months since completion)
- Consent to provide tissue samples for the study
- Dysphagia grade ≤2
Exclusion Criteria (for both groups of patients):
- Patients currently on anticoagulant treatment (warfarin, acenocoumarol) with no possibility of stopping / modification
- Dysphagia grade ≥3 (able to swallow only liquid foods)
- History of myocardial infarction or other cardiovascular event within 6 months of enrolment
- Neurological diseases associated with impaired swallowing
- Patients in long-term care or institutional care (physical, psycho-social disorders, intellectual disability).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cytosponge
This part of the study will have an active prospective recruitment of patients. Recruitment will involve two patient populations:
Following inclusion in the study, subjects will be asked to complete a behavior questionnaire, have blood collected, and undergo a Cytosponge™ procedure followed by diagnostic gastroscopy using advanced imaging with biopsies. During gastroscopy, additional tissue samples will be collected for research purposes. These samples, along with cytological specimens from the Cytosponge™, will be analyzed to assess the diagnostic accuracy of biomarkers in the diagnosis of LG-IEN, HG-IEN, and ESCC. |
The Cytosponge™ is a minimally-invasive sampling device consisting of a polyurethane sponge compressed in a cellophane capsule attached to a string.
When swallowed, the capsule dissolves in the stomach, releasing the cell collection sponge that expands to 3 cm in diameter.
Next, a nurse or qualified medical technician retrieves the sponge by pulling back on the string and retracting it through the mouth.
During extraction, the rough texture on the surface of the sponge collects epithelial cells in the cardia and along the entire length of the esophagus.
Cytosponge™ has excellent safety profile and is approved by the Food and Drug Administration (FDA) and the Healthcare Products Regulatory Agency (HPRA) in the UK.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Discovery of suitable biomarkers for squamous intraepithelial neoplasia to inform future trials.
Time Frame: 4 years
|
RNA-seq expression analysis will be used to measure the abundance of the previously identified biomarkers of squamous intraepithelial neoplasia, including genes TP53, NFE2L2, MLL2, ZNF750, NOTCH1, TFNAIP3, and CHN1.
The study will include these biomarkers, but will not be limited to them.
|
4 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability of the Cytosponge™ cell collection device in patients with ESCC and high-risk for ESCC
Time Frame: 4 years
|
% of Participants that have scored the Cytosponge experience of at least 6 points on a 0 to 10 Visual Analogue Scale (VAS) acceptability scale whereby 0 denotes "worst experience in life" and 10 denotes "best experience in life".
|
4 years
|
Safety of the Cytosponge™ cell collection device in patients with ESCC and high-risk for ESCC: rate of Participants with adverse events within 30 days after application
Time Frame: 4 years
|
The rate of Participants with adverse events within 30 days after application of the Cytosponge cell collection device, which is defined as any event that require admission to the hospital.
E.g. retention of the device in the GI tract, chest pain or gastrointestinal bleeding requiring admission to the Ward
|
4 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Wladyslaw Januszewicz, M.D., Centre of Postgraduate Medical Education, Warsaw, Poland
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 109/PB/2019
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Cancer
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnStage IIB Esophageal Cancer AJCC v7 | Stage III Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedEsophageal Cancer | Gastrooesophageal Cancer | Oesophageal Cancer | GastroEsophageal Cancer | Esophageal Cancers NOS | Oesophageal Cancer Metastatic | Esophageal Cancer Metastatic | Oesophageal Cancer NosGermany
-
National Cancer Institute (NCI)NRG OncologyCompletedEsophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IB Esophageal Cancer AJCC v7United States
-
University of Wisconsin, MadisonActive, not recruitingResectable Esophageal Cancer | GastroEsophageal CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7 | Malignant Neoplasm of the Cervical Esophagus | Malignant Neoplasm...United States
-
Cancer Institute and Hospital, Chinese Academy...Tianjin Medical University Cancer Institute and Hospital; Sichuan Cancer Hospital...UnknownEsophageal Neoplasm | Esophageal Cancer TNM Staging Primary Tumor (T) T3 | Esophageal Cancer TNM Staging Primary Tumor (T) T2 | Esophageal Cancer TNM Staging Regional Lymph Nodes (N) N0 | Esophageal Cancer TNM Staging Distal Metastasis (M) M0China
-
Tianjin Medical University Cancer Institute and...Sun Yat-sen University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaboratorsNot yet recruitingStage III Esophageal Cancer | Stage II Esophageal Cancer
-
Tianjin Medical University Cancer Institute and...UnknownStage III Esophageal Cancer | Stage II Esophageal CancerChina
-
Academisch Medisch Centrum - Universiteit van Amsterdam...UMC UtrechtCompletedEsophageal Cancer, Stage II | Esophageal Cancer Stage IIINetherlands
-
Tianjin Medical University Cancer Institute and...The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaboratorsUnknownEsophageal Cancer Stage III | Esophageal Cancer Stage IIBChina
Clinical Trials on Cytosponge cell collection device
-
University of North Carolina, Chapel HillMayo Clinic; University of Cambridge; CURED FoundationTerminatedEosinophilic Esophagitis | EoEUnited States
-
Medtronic - MITGCompleted
-
University of North Carolina, Chapel HillAmerican Gastroenterological AssociationCompletedGERD | Barrett EsophagusUnited States
-
Mayo ClinicNational Cancer Institute (NCI); Exact Sciences CorporationCompletedBarrett EsophagusUnited States
-
Lucid Diagnostics, Inc.RecruitingBarrett Esophagus | Esophageal Adenocarcinoma | Barrett's Esophagus Without Dysplasia | Barretts Esophagus With DysplasiaUnited States, Netherlands
-
Abbott Medical DevicesCompleted
-
Terumo BCTYale University; Versiti; Key Biologics, LLC; LeukoLabCompleted
-
Velano Vascular, Inc.Completed
-
Loyola UniversityRecruitingUrinary Tract Infections | Asymptomatic BacteriuriaUnited States
-
Teal Health, Inc.Enrolling by invitationHPV Infection | HPV 16 Infection | Hpv | High Risk HPVUnited States